IMNM
$20.71
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset compris...
Recent News
Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative?
Immunome, Inc. recently reported a lower full-year net loss for 2025, updated investors on progress in its oncology pipeline, and filed a US$156.03 million common stock shelf registration tied to an ESOP-related offering. A key angle for investors is how reduced losses alongside an expanded late-stage cancer portfolio and potential future equity issuance could shape Immunome’s financial and operational flexibility. Next, we will examine how Immunome’s reduced net loss and plans to file a New...
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development
Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc. (NASDAQ:IMNM) CEO and Chairman Clay Siegall reiterated heightened focus on building an oncology-focused pipeline centered on cell-surface-targeting agents and small molecules. The ultimate goal is to develop a targeted oncology platform for small molecules that can […]
Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback
Immunome stock performance snapshot Immunome (IMNM) has drawn fresh attention after recent share price swings, with the stock up about 1.5% over the past day but showing a roughly 14% decline over the past month. See our latest analysis for Immunome. At the current share price of $22.12, Immunome’s recent 1 month share price return of about a 14% decline contrasts with a 90 day share price return of 18.7% and a very large 3 year total shareholder return. This suggests longer term momentum,...
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.